Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
34 hedge funds and large institutions have $27.6M invested in Cellular Biomedicine Group, Inc. in 2018 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 7 closing their positions.
600% more call options, than puts
Call options by funds: $21K | Put options by funds: $3K
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
127% more capital invested
Capital invested by funds: $12.2M → $27.6M (+$15.4M)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
36% more funds holding
Funds holding: 25 → 34 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.35M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.44M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$820K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$644K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$636K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.84M |
| 2 |
Goldman Sachs
New York
|
-$927K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$755K |
| 4 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
-$487K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
-$67K |
CBMG Hedge Fund Activity: Q2 2018 in Review
34 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q2 2018, worth a combined $27.6M — up 127% from $12.2M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CBMG positions and 7 closed out — a net gain of 9 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $9.35M. The largest seller was Millennium Management, exiting entirely with an estimated $1.84M sold.
- 34 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q2 2018, up from 25 in Q1 2018.
- Funds reported $27.6M of Cellular Biomedicine Group, Inc. stock for Q2 2018, up 127% quarter-over-quarter.
- 16 funds opened new Cellular Biomedicine Group, Inc. positions in Q2 2018 and 7 closed out, a net change of +9 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q2 2018 was BlackRock, an estimated $9.35M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q2 2018 was Millennium Management, an estimated $1.84M sold.
Based on aggregated 13F filings for Q2 2018.